LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

NVS

144.93

-0.69%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

NVS

144.93

-0.69%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

NVS

144.93

-0.69%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

NVS

144.93

-0.69%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

NVS

144.93

-0.69%↓

MRK

111.34

+0.09%↑

Home・Listă Acțiuni・Dynavax Technologies Corp

Dynavax Technologies Corp

Închisă

SectorSănătate

15.49

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

15.49

Maxim

15.49

Indicatori cheie
By Trading Economics
Venit	8.2M 27M
Vânzări	-566K 95M
Marjă de profit	28.381
Angajați	405
EBITDA	7M 32M

Dividende
By Dow Jones
Următoarele câștiguri	19 feb. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	625M 1.8B
Deschiderea anterioară	15.49
Închiderea anterioară	15.49

Sentimentul știrilor

By Acuity

18%

82%

26 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

9.62 / 10.9 Suport & Rezistență

Dynavax Technologies Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 dec. 2025, 11:40 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal -- Update

24 dec. 2025, 11:17 UTC

Principalele dinamici ale pieței

Achiziții, Fuziuni, Preluări

Dynavax Shares Leap Premarket on Takeover by Sanofi

24 dec. 2025, 06:55 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

12 ian. 2026, 19:24 UTC

Achiziții, Fuziuni, Preluări

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 ian. 2026, 19:22 UTC

Achiziții, Fuziuni, Preluări

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

24 dec. 2025, 17:08 UTC

Achiziții, Fuziuni, Preluări

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec. 2025, 12:59 UTC

Achiziții, Fuziuni, Preluări

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec. 2025, 06:41 UTC

Achiziții, Fuziuni, Preluări

Correct: Sanofi: Deal Expected to Have No Impact on 2025 Guidance

24 dec. 2025, 06:19 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Acquisition to Close in 1Q of 2026

24 dec. 2025, 06:19 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Deal Expected to Have on Impact on 2025 Guidance

24 dec. 2025, 06:19 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Offering $15.50 a Share in Cash for Dynavax

24 dec. 2025, 06:18 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Start Cash Tender Offer at Equity Value of $2.2B

24 dec. 2025, 06:18 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Deal Adds Marketed Adult Hepatitis B Vaccine, Phase 1/2 Shingles Candidate

24 dec. 2025, 06:17 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Vaccine Company Dynavax Technologies

24 dec. 2025, 06:16 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Dynavax

Comparație

Modificare preț

Dynavax Technologies Corp Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 0 analiști care au acordat evaluări ale acțiunilor Dynavax Technologies Corp - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

9.62 / 10.9Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

26 / 352 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Dynavax Technologies Corp

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.